BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Zabriskie, Matthew S.; Eide, Christopher A.; Tantravahi, Srinivas K.; Vellore, Nadeem A.; Estrada, Johanna; Nicolini, Franck E.; Khoury, Hanna J.; Larson, Richard A.; Konopleva, Marina; Cortes, Jorge E.; Kantarjian, Hagop; Jabbour, Elias J.; Kornblau, Steven M.; Lipton, Jeffrey H.; Rea, Delphine; Stenke, Leif; Barbany, Gisela; Lange, Thoralf; Hernández-Boluda, Juan-Carlos; Ossenkoppele, Gert J.; Press, Richard D.; Chuah, Charles; Goldberg, Stuart L.; Wetzler, Meir; Mahon, Francois-Xavier; Etienne, Gabriel; Baccarani, Michele; Soverini, Simona; Rosti, Gianantonio; Rousselot, Philippe; Friedman, Ran; Deininger, Marie; Reynolds, Kimberly R.; Heaton, William L.; Eiring, Anna M.; Pomicter, Anthony D.; Khorashad, Jamshid S.; Kelley, Todd W.; Baron, Riccardo; Druker, Brian J.; Deininger, Michael W.; O’Hare, Thomas

doi:10.1016/j.ccr.2014.07.006

Title: BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Full Record
Other Related Research

Authors:: Zabriskie, Matthew S.; Eide, Christopher A.; Tantravahi, Srinivas K.; Vellore, Nadeem A.; Estrada, Johanna; Nicolini, Franck E.; Khoury, Hanna J.; Larson, Richard A.; Konopleva, Marina; Cortes, Jorge E.; Kantarjian, Hagop; Jabbour, Elias J.; Kornblau, Steven M.; Lipton, Jeffrey H.; Rea, Delphine; Stenke, Leif; Barbany, Gisela; Lange, Thoralf; Hernández-Boluda, Juan-Carlos; Ossenkoppele, Gert J. more »« less

Publication Date:: Mon Sep 01 00:00:00 EDT 2014

Sponsoring Org.:: USDOE

OSTI Identifier:: 1402175

Resource Type:: Published Article

Journal Name:: Cancer Cell

Additional Journal Information:: Journal Name: Cancer Cell Journal Volume: 26 Journal Issue: 3; Journal ID: ISSN 1535-6108

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Citation Formats


                    Zabriskie, Matthew S., Eide, Christopher A., Tantravahi, Srinivas K., Vellore, Nadeem A., Estrada, Johanna, Nicolini, Franck E., Khoury, Hanna J., Larson, Richard A., Konopleva, Marina, Cortes, Jorge E., Kantarjian, Hagop, Jabbour, Elias J., Kornblau, Steven M., Lipton, Jeffrey H., Rea, Delphine, Stenke, Leif, Barbany, Gisela, Lange, Thoralf, Hernández-Boluda, Juan-Carlos, Ossenkoppele, Gert J., Press, Richard D., Chuah, Charles, Goldberg, Stuart L., Wetzler, Meir, Mahon, Francois-Xavier, Etienne, Gabriel, Baccarani, Michele, Soverini, Simona, Rosti, Gianantonio, Rousselot, Philippe, Friedman, Ran, Deininger, Marie, Reynolds, Kimberly R., Heaton, William L., Eiring, Anna M., Pomicter, Anthony D., Khorashad, Jamshid S., Kelley, Todd W., Baron, Riccardo, Druker, Brian J., Deininger, Michael W., and O’Hare, Thomas. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.  United States: N. p., 2014. 
Web.  doi:10.1016/j.ccr.2014.07.006.

Copy to clipboard


                    Zabriskie, Matthew S., Eide, Christopher A., Tantravahi, Srinivas K., Vellore, Nadeem A., Estrada, Johanna, Nicolini, Franck E., Khoury, Hanna J., Larson, Richard A., Konopleva, Marina, Cortes, Jorge E., Kantarjian, Hagop, Jabbour, Elias J., Kornblau, Steven M., Lipton, Jeffrey H., Rea, Delphine, Stenke, Leif, Barbany, Gisela, Lange, Thoralf, Hernández-Boluda, Juan-Carlos, Ossenkoppele, Gert J., Press, Richard D., Chuah, Charles, Goldberg, Stuart L., Wetzler, Meir, Mahon, Francois-Xavier, Etienne, Gabriel, Baccarani, Michele, Soverini, Simona, Rosti, Gianantonio, Rousselot, Philippe, Friedman, Ran, Deininger, Marie, Reynolds, Kimberly R., Heaton, William L., Eiring, Anna M., Pomicter, Anthony D., Khorashad, Jamshid S., Kelley, Todd W., Baron, Riccardo, Druker, Brian J., Deininger, Michael W., & O’Hare, Thomas. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.  United States.  https://doi.org/10.1016/j.ccr.2014.07.006

Copy to clipboard


                    Zabriskie, Matthew S., Eide, Christopher A., Tantravahi, Srinivas K., Vellore, Nadeem A., Estrada, Johanna, Nicolini, Franck E., Khoury, Hanna J., Larson, Richard A., Konopleva, Marina, Cortes, Jorge E., Kantarjian, Hagop, Jabbour, Elias J., Kornblau, Steven M., Lipton, Jeffrey H., Rea, Delphine, Stenke, Leif, Barbany, Gisela, Lange, Thoralf, Hernández-Boluda, Juan-Carlos, Ossenkoppele, Gert J., Press, Richard D., Chuah, Charles, Goldberg, Stuart L., Wetzler, Meir, Mahon, Francois-Xavier, Etienne, Gabriel, Baccarani, Michele, Soverini, Simona, Rosti, Gianantonio, Rousselot, Philippe, Friedman, Ran, Deininger, Marie, Reynolds, Kimberly R., Heaton, William L., Eiring, Anna M., Pomicter, Anthony D., Khorashad, Jamshid S., Kelley, Todd W., Baron, Riccardo, Druker, Brian J., Deininger, Michael W., and O’Hare, Thomas. Mon .  
"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia".  United States.  https://doi.org/10.1016/j.ccr.2014.07.006.

Copy to clipboard


                    
@article{osti_1402175,

  title        = {BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia},

  author       = {Zabriskie, Matthew S. and Eide, Christopher A. and Tantravahi, Srinivas K. and Vellore, Nadeem A. and Estrada, Johanna and Nicolini, Franck E. and Khoury, Hanna J. and Larson, Richard A. and Konopleva, Marina and Cortes, Jorge E. and Kantarjian, Hagop and Jabbour, Elias J. and Kornblau, Steven M. and Lipton, Jeffrey H. and Rea, Delphine and Stenke, Leif and Barbany, Gisela and Lange, Thoralf and Hernández-Boluda, Juan-Carlos and Ossenkoppele, Gert J. and Press, Richard D. and Chuah, Charles and Goldberg, Stuart L. and Wetzler, Meir and Mahon, Francois-Xavier and Etienne, Gabriel and Baccarani, Michele and Soverini, Simona and Rosti, Gianantonio and Rousselot, Philippe and Friedman, Ran and Deininger, Marie and Reynolds, Kimberly R. and Heaton, William L. and Eiring, Anna M. and Pomicter, Anthony D. and Khorashad, Jamshid S. and Kelley, Todd W. and Baron, Riccardo and Druker, Brian J. and Deininger, Michael W. and O’Hare, Thomas},

  abstractNote = {},

  doi          = {10.1016/j.ccr.2014.07.006},

  journal      = {Cancer Cell},

  number       = 3,

  volume       = 26,

  place        = {United States},

  year         = {Mon Sep 01 00:00:00 EDT 2014},

  month        = {Mon Sep 01 00:00:00 EDT 2014}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
https://doi.org/10.1016/j.ccr.2014.07.006

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 227 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias

Journal Article Muller, A J ; Witte, O N ; Young, J C ; ... - Molecular and Cellular Biology; (United States)

The c-abl proto-oncogene encodes a cytoplasmic tyrosine kinase which is homologous to the src gene product in its kinase domain and in the upstream kinase regulatory domains SH2 (src homology region 2) and SH3 (src homology region 3). The murine v-abl oncogene product has lost the SH3 domain as a consequence of N-terminal fusion of gag sequences. Deletion of the SH3 domain is sufficient to render the murine c-abl proto-oncogene product transforming when myristylated N-terminal membrane localization sequences are also present. In contrast, the human BCR/ABL oncogene of the Philadelphia chromosome translocation has an intact SH3 domain and its productmore »« less
https://doi.org/10.1128/MCB.11.4.1785
HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1

Journal Article Bamodu, Oluwaseun Adebayo ; Department of Medical Research & Education, Taipei Medical University – Shuang Ho Hospital, New Taipei City, Taiwan, ROC ; Kuo, Kuang-Tai ; ... - Experimental Cell Research

Highlights: • hsa-miR-196a mediates inhibition of CML stem cells. • Potentiate the anticancer effect of Imatinib mesylate by suberanilohydroxamic acid. • Synergism with Imatinib mesylate and suberanilohydroxamic acid reverses the tumor-promoting proteotranscriptomic profile. Failure to eradicate hematologic cancer stem cells (hCSCs) associated with resistance to tyrosine kinase inhibitors such as imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is a clinical challenge that highlights the need for discovering and developing therapeutic strategies that target and eliminate these hCSCs. Herein, we document the essential role of the interplay between histone deacetylases (HDACs), the polycomb group proteins, pluripotency transcription factors andmore »« less
https://doi.org/10.1016/J.YEXCR.2018.07.017
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

Journal Article Zhou, Tianjun ; Commodore, Lois ; Huang, Wei-Sheng ; ... - Chem. Biol. Drug Des.

The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia. However, drug resistance caused by kinase domain mutations has necessitated the development of new mutation-resistant inhibitors, most recently against the T315I gatekeeper residue mutation. Ponatinib (AP24534) inhibits both native and mutant BCR-ABL, including T315I, acting as a pan-BCR-ABL inhibitor. Here, we undertook a combined crystallographic and structure-activity relationship analysis on ponatinib to understand this unique profile. While the ethynyl linker is a key inhibitor functionality that interacts with the gatekeeper, virtually all other components of ponatinib play an essential role in its T315I inhibitory activity. The extensive networkmore »« less
https://doi.org/10.1111/j.1747-0285.2010.01054.x
Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia

Journal Article Gupta, Manu ; Milani, Lili ; Hermansson, Monica ; ... - Biochemical and Biophysical Research Communications

Using a quantitative single nucleotide polymorphism (SNP) assay we have investigated the changes in the expression of the BCR-ABL1 oncogene relative to the wild-type ABL1 and BCR alleles in cells from chronic myeloid leukemia (CML) patients not responding to therapy. The results show a progressive increase in the BCR-ABL1 oncogene expression at the expense of decreased expression of the ABL1 allele, not involved in the fusion. No relative changes in the expression of the two BCR alleles were found. These results demonstrate that allele-specific changes in gene expression, with selective, progressive silencing of the wild-type ABL1 allele in favor ofmore »« less
https://doi.org/10.1016/j.bbrc.2007.12.029
Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells

Journal Article Okabe, Seiichi ; Tauchi, Tetsuzo ; Tanaka, Yuko ; ... - Biochemical and Biophysical Research Communications

Highlights: •Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells okabe et al. •Imatinib or nilotinib resistance was involved Src family kinase. •The BCR-ABL point mutation (E334V) was highly resistant to imatinib or nilotinib. •Ponatinib was a powerful strategy against imatinib or nilotinib resistant Ph-positive cells. -- Abstract: Because a substantial number of patients with chronic myeloid leukemia acquire resistance to ABL tyrosine kinase inhibitors (TKIs), their management remains a challenge. Ponatinib, also known as AP24534, is an oral multi-targeted TKI. Ponatinib is currently being investigated in a pivotal phase 2 clinical trial. In the present study, we analyzedmore »« less
https://doi.org/10.1016/J.BBRC.2013.05.022

Similar Records